

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

QUALICAPS CO., LTD,
Patent Owner.

Case IPR2017-00203
Patent 6,649,180

**DECLARATION OF JASON T. McCONVILLE, PH.D.
IN SUPPORT OF PATENT OWNER RESPONSE
PURSUANT TO 37 C.F.R. § 42.120**

Table of Contents

	<u>Page</u>
I. PRELIMINARY STATEMENT	1
II. ACADEMIC AND PROFESSIONAL QUALIFICATIONS	1
III. RELATIONSHIP TO THE PARTIES	5
IV. LEVEL OF ORDINARY SKILL IN 1999	6
V. THE INVENTION OF THE '180 PATENT	8
A. The Problem Discovered and Solved by the Inventors	8
B. The Criticality of the Claimed MO/HPO Upper Limits	9
C. The '180 Patent Claims	13
VI. BACKGROUND OF HARD CAPSULE TECHNOLOGY AND HPMC	14
A. State of the Hard Capsule Art in 1999	14
B. Hydroxypropyl Methylcellulose ("HPMC") Substitution Types	17
VII. THE CITED ART	24
A. Yamamoto '123 Patent	24
B. The Japanese Pharmacopoeia	29
VIII. YAMAMOTO AND THE JP WOULD HAVE TAUGHT A POSA THAT ONLY HPMC 2910 WAS ACCEPTABLE FOR HARD CAPSULE FILMS	29
A. The Prior Art Instructed a POSA to use HPMC 2910 for Film Compositions	30
1. Yamamoto's Reported Optimized Viscosity Confirms Using Only HPMC 2910 for Film Compositions.	35

B. The Unpredictability of the Different Substitution Chemistries Confirms Yamamoto’s Use of Only HPMC 2910 for Capsule Film Compositions38

C. The Requirements for Preparing Successful Hard Capsules Further Directed a POSA to Use Only HPMC 291040

IX. A POSA WOULD HAVE UNDERSTOOD THAT MO/HPO CONTENT IN EACH HPMC SUBSTITUTION TYPE COMPLIED WITH THE MANUFACTURER’S DESIGNATION45

X. A POSA WOULD NOT HAVE EXPECTED THAT HPMC 2910 CAPSULES AVOIDED GELLING AID PRECIPITATION DEFECTS49

 1. The Cited Art Does Not Disclose Capsules that Inherently Avoided Gelling Aid Precipitation.....54

XI. CONCLUSION.....57

I, Jason T. McConville, hereby declare and state as follows:

I. PRELIMINARY STATEMENT

1. I have been retained on behalf of Patent Owner Qualicaps Co., Ltd. (“Patent Owner” or “Qualicaps”) to provide evidence in *Mylan Pharmaceuticals Inc. v. Qualicaps Co., Ltd*, Case IPR2017-00203. I am being compensated at my usual and customary hourly rate for my services in connection with this *Inter Partes* Review proceeding. My compensation is not dependent upon the outcome of the present *Inter Partes* review proceeding.

2. I have reviewed the Petition for *Inter Partes* Review of Patent No. 6,649,180 (“the ’180 patent”) filed by Mylan Pharmaceuticals Inc. (“Petitioner”), including Dr. Kibbe’s Declaration (Ex. 1011), as well as the exhibits and articles cited in those documents. I have also reviewed the articles and documents cited in this declaration.

3. I am aware of information generally available to, and relied upon by, persons of ordinary skill in the art at the relevant times. Some statements below are expressly based on such awareness.

II. ACADEMIC AND PROFESSIONAL QUALIFICATIONS

4. I am an Associate Professor of Pharmaceutics at the University of New Mexico College of Pharmacy and an Adjunct Professor at the University of Bonn, in the Department of Pharmaceutical Technology, in Bonn, Germany.

5. I received my Bachelor of Science, with Honors, in Applied Chemistry from Coventry University, in Coventry, United Kingdom in 1994. From 1994 to 1999, I was a Research Technician in Pharmaceutics at the Centre for Drug Formulation Studies at the University of Bath, in Bath, United Kingdom. My main research project pertained to controlled release drug delivery, and specifically hydrophilic gel formation and drug release. My responsibilities included preparation and testing of pharmaceutical formulations. These were done under the direction of the Principal Investigator, who provided the instruction on which materials to use in the formulations. I did not devise new combinations of materials or new uses for known materials. I would primarily consult manufacturer-provided information on specific substances and, with regard to testing methodology, the relevant pharmacopoeia in effect at the time. Additionally, I would refer to current literature for experimental guidance on standardized methods. I relied on labels and other identifying information on containers of materials I used to be certain I was using the correct materials.

6. I subsequently earned my Ph.D. in Pharmaceutics from the University of Strathclyde, in Glasgow, United Kingdom in 2002. My Ph.D. dissertation was titled "Pulsed-Release Drug Delivery and Development of the Time-Delayed Capsule." After earning my Ph.D., I was a Post-Doctoral Fellow at the University of Texas at Austin College of Pharmacy from 2002 to 2006.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.